AKBA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKBA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Akebia Therapeutics has the GF Score of 59, which implies that the company might have Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
1. Financial Strength : 3/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Akebia Therapeutics might have Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Akebia Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's GF Score falls into.
Akebia Therapeutics (NAS:AKBA) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score | Performance Potential and All-in-One Screener Examples (1) |
91 - 100 | Highest outperformance potential |
81 - 90 | Good outperformance potential |
71 - 80 | Likely to have average performance |
51 - 70 | Poor future performance potential |
0 - 50 | Worst future performance potential, or not enough data |
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Thank you for viewing the detailed overview of Akebia Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Ellen Snow | officer: SVP, CFO and Treasurer | C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109 |
Michel Dahan | officer: SVP, Chief Business Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Nicole R. Hadas | officer: SVP, General Counsel, Sec. | 20 PILGRAM DRIVE, WINCHESTER MA 01890 |
David A Spellman | officer: SVP, CFO and Treasurer | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Steven Keith Burke | officer: SVP, Chief Medical Officer | 82 WILLIS ROAD, SUDBURY MA 01776 |
John P. Butler | director, officer: CEO & President | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Violetta Cotreau | officer: SVP, Chief Accounting Officer | 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142 |
Ron Frieson | director | 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142 |
Dell Faulkingham | officer: CCO | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Leanne M Zumwalt | director | C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037 |
Maxine Gowen | director | |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Myles Wolf | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Karen L Tubridy | officer: SVP, Chief Development Officer | ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire • 11-01-2023
By PRNewswire • 06-30-2023
By PRNewswire • 11-02-2023
By PRNewswire • 09-25-2023
By PRNewswire • 08-10-2023
By PRNewswire • 07-18-2023
By PRNewswire • 12-01-2023
By PRNewswire • 09-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.